Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...

Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

With the purchase of a plant in the Czech Republic, Novo Nordisk is saying “jak se máš” to hundreds of new employees—and ...

Merus’ week keeps getting better. Days after securing a long-awaited commercialization partner for its zenocutuzumab, the ...

Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...

With AstraZeneca’s former international chief, Leon Wang, under investigation in China, the company has promoted an AZ ...

The latest iteration of the campaign builds on Sumitomo’s work to expand the Go-Getter program. The “Time to Go” website now ...

How well a certain treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) works can vary ...

Following a pair of similar deals in January and June, Coherus BioSciences has netted itself a hefty chunk of change for the ...

On the heels of similar deals in the U.S. and the EU, the U.K. is filling up its coffers with doses of bird flu immunizations ...

While healthcare was not a major campaign issue in the most recent U.S. election, President-elect Donald Trump, empowered by ...